In this study, Nightingale’s blood biomarker analysis service was used to quantify metabolic measures (including detailed lipid and lipoprotein particle profiles), for 1,810 individuals (N fatty liver =338) from The Cardiovascular Risk in Young Finns Study.

This study illustrates how combining genetic and metabolic profiling could enhance better classification and targeted treatment of NAFLD subtypes.